Table 3:

Immune-related adverse events by dose and grade

	1 mg/kg (n=3)		3 mg/kg (n=6)		5 mg/kg (n=6)		10 mg/kg (n=15)		Total (n=30)
	Grade 2	Grade 3	Grade 2	Grade 3/4	Grade 2	Grade 3	Grade 2	Grade 3/4	Grade 2–4
Diarrhoea or colitis	0	0	1	1 (grade 3)	1	1	2	2 (1 grade 3 plus 1 grade 4)	8
Rash	0	0	1	0	1	0	6	2 (grade 3)	10
Panhypophysitis	0	0	0	0	2	0	1	1 (grade 3)	4
Hypothyroidism	0	0	0	0	2	0	2	0	4
Adrenal insufficiency	0	0	0	0	0	1	1	1 (grade 3)	3
Raised aminotransferases	0	0	0	0	0	0	1	2 (grade 3)	3
Neutropenia	0	0	0	1 (grade 4)	1	0	0	0	2
Total (proportion of ipilimumab cycles)	0 (0%)	0 (0%)	2 (14%)	2 (14%)	7 (41%)	2 (12%)	13 (28%)	8 (18%)	··
Total for grades 2–4 (proportion of ipilimumab cycles	··	0 (0%)	··	4 (28%)	··	9 (53%)	··	21 (46%)	34 (40%)

Data are number of events; some patients had more than one event.